NBTX Company Profile and Key Details

Q: Who are the executives of NBTX?

Mr. Earl J. Bergey Ph.d.Co-FounderMs. Kathryn M. McNeilSenior Vice President of Investor RelationsProf. Para Prasad Ph.D.Co-Founder and Member of Scientific BoardMr. Laurent Levy Ph.D.Co-Founder, Pres of the Executive Board & Chief Executive OfficerMr. Bart Van RhijnChief Financial Officer & Member of Executive BoardMr. Alain DostieChief Operating OfficerMs. Elsa BorghiHead of Innovation & Drug DiscoveryMs. Anne-Juliette Hermant M.A.Chief People Officer & Member of Executive BoardMs. Sarah GaubertHead of Communication & Public Affairs DepartmentMs. Margaret GalluzziVice President & Global Head of Clinical OperationsMr. Patrick Tricoli M.B.A., Pharm.D.Global Head of Bus. Devel.Mr. Ventzislav Vassilev M.D.Vice President & Global Head of Safety Vigilance

NASDAQ : NBTX

Nanobiotix SA

$33.05

-2.83-7.89%

At Close 4:00 PM

62.39

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Nanobiotix S.A. (NBTX) stock declined over -7.89%, trading at $33.05 on NASDAQ, down from the previous close of $35.88. The stock opened at $34.89, fluctuating between $33.01 and $35.23 in the recent session.

Stock Snapshot

35.88

Prev. Close

1.67B

Market Cap

33.01

Day Low

-55.85

P/E Ratio

-0.59176

EPS (TTM)

-1.08

Cash Flow per Share

34.89

Open

50.6M

Number of Shares

35.23

Day High

79.98%

Free Float in %

-1.54

Book Value

149.34K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 18, 2026	34.89	35.60	33.01	33.05	149.34K
Sep 17, 2026	34.63	35.96	34.63	35.88	99.77K
Sep 16, 2026	34.64	35.34	33.80	34.40	198.7K
Sep 15, 2026	36.06	36.99	35.25	35.26	135.73K
Sep 14, 2026	36.00	36.89	34.89	35.73	128.5K
Sep 11, 2026	37.00	37.70	36.43	37.01	93.82K
Sep 10, 2026	36.99	38.81	36.62	37.60	200.14K
Sep 09, 2026	35.45	36.72	35.45	36.64	104.83K
Sep 08, 2026	37.94	39.15	37.48	38.19	102.9K
Sep 04, 2026	39.01	40.99	38.43	38.80	119.3K
Sep 03, 2026	41.67	41.73	39.11	40.00	97.04K
Sep 02, 2026	41.40	43.40	40.20	41.67	185.26K
Sep 01, 2026	39.28	41.36	38.60	39.29	91.34K
Aug 31, 2026	41.23	41.41	40.01	40.64	113.7K
Aug 28, 2026	44.55	45.03	40.49	41.23	164.84K
Aug 27, 2026	42.63	46.69	42.49	45.16	347.8K
Aug 26, 2026	41.33	44.50	39.89	44.50	240.41K
Aug 25, 2026	40.13	42.42	40.13	41.51	177.92K
Aug 24, 2026	40.72	40.86	39.22	39.66	223.88K
Aug 21, 2026	43.11	44.85	43.11	43.55	74.31K

Contact Details

Paris, IF 75012

France

https://www.nanobiotix.com 331 402 60470

About Company

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

Stock Peers

ARGX

-5.45-0.55%

argenx SE$990.32 REGN

-4.6-0.58%

Regeneron Pharmaceuticals, Inc.$784.85 MDGL

-2.88-0.54%

Madrigal Pharmaceuticals, Inc.$531.52 VRTX

-8.00008-1.55%

Vertex Pharmaceuticals Incorporated$508.34 UTHR

-2.64-0.53%

United Therapeutics Corporation$494.63 ONC

-2.62-0.74%

BeOne Medicines AG$350.84 KRYS

-2.08-0.61%

Krystal Biotech, Inc.$336.67 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-11.52-3.71%

Praxis Precision Medicines, Inc.$298.95 LGND

-1.21-0.43%

Ligand Pharmaceuticals Incorporated$283.49

Company Overview

Nanobiotix S.A. (NASDAQ:NBTX) closed at $33.05 USD, losing -$2.83 (-7.89%) from the previous close of $35.88. The stock is currently mid-range between its 52-week high and low $12.63 and $57.14. With a market capitalization of about $1.67 billion, Nanobiotix S.A. is classified as a small-cap and shows lower-than-market volatility (beta ~0.57). Key stats such as the average daily volume over the past year has been around 139.03 thousand shares, in line with its 52-week average. Headquartered in Paris, IF, Nanobiotix S.A. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Laurent Levy, the company employs approximately 97 people and listed since December 11, 2020. Nanobiotix S.A.

Technical Performance

NBTX has shown mixed momentum, gaining 4.58% over the past week and -18.01% over the past quarter, though year-to-date performance is down -9.21%. Short-term trend indicators are bearishly aligned (SMA20 14.31%, SMA50 21.61%, SMA200 86.79%). The stock’s 14-day RSI is 65.37 (firm momentum), while the ATR of 1.44 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.36% below its high and over 832.54% above its low. Average 10-day trading volume of 138.85 thousand shares is in line with the 3-month average of 139.15 thousand, indicating normal recent market interest.

Valuation Metrics

Nanobiotix S.A. trades at a P/E ratio of -58.51, slightly below the S&P 500 average, with a price-to-sales ratio of 49.94 and a price-to-book ratio of -16.56 indicating negative book value, which may reflect financial stress. The P/FCF stands at -43.58, also below market averages.

Dividend & Fair Value

Nanobiotix S.A. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$5.69. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Nanobiotix S.A. generated EPS of $nan over the past year. Five-year average earnings growth is 9.96%. Wall Street analysts project EPS growth of 28.37% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $64.00 to $26.00. The high target offers 93.65% upside. The low target suggests -21.33% downside. The mean target is $40.40. This offers 22.24% upside. Nanobiotix S.A. earnings surprise history is frequent misses against expectations. The quarter that ended March 31, 2026, missed forecasts by -250.74%. The prior quarter beat by -45.89%. Over the last six quarters, Apple has recorded several small beats. These include -69.96% in April 24, 2024.

Shareholding & Insider Activity

Nanobiotix S.A. has 50.80 million shares outstanding. The public float is 31.95 million shares, elevated short interest at 0.27% of float. This equals 99.41 thousand shares. The short ratio is 0.8 days. Institutional investors hold 11.75% of the float. Insiders own 0.0%.

Financial & Profitability Overview

Over the trailing twelve months, Nanobiotix SA generated $30.06M in revenue, or $0.81 per share. Gross margin was 100.00%, operating margin -89.09%, and net profit margin -132.08%. Returns are negative, with ROA at -66.42% and ROE at 146.79%.
On valuation metrics, Nanobiotix SA trades at a P/E of -58.51, P/S of 49.94 and P/B of -16.56. The current ratio is 1.09 and quick ratio is 1.09. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 94.57 days. Debt-to-equity is -1.13, supported by a cash flow-to-debt ratio of -0.35.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Nanobiotix SA posted revenue of $30.06M, down slightly from $4.78M in the prior quarter. Gross profit was $30.06M (margin 100.00%). Operating income was - $26.78M (margin -89.1%). Net income was- $39.70M (EPS - $1.08).
The company ended the quarter with $41.39M in cash and short-term investments, a total debt of $53.17M, and net debt of $11.78M. Total assets were $59.77M, with equity of - $27.05M. Financials further reflected weakness, with operating cash flow of - $37.10M, free cash flow of - $37.20M, and capital expenditures of - $93.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Nanobiotix S.A. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.65%, with price expected at $28.87 by October 02, 2026, within a range of $26.82 to $30.80 3-Month Outlook: Projected rise of 33.19%, reaching $44.02 by December 16, 2026, with a range of $43.40 to $44.73. 1-Year Outlook: Projected gain of 38.52%, with price at $45.78 by September 17, 2027, within a range of $42.52 to $49.13.

Key Takeaways

Nanobiotix S.A. (NASDAQ:NBTX) shares are flat -9.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Nanobiotix S.A. trading at a premium to the broader market with a P/E of -58.51. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $29.12, suggesting -11.89% downside. Our AI forecast model points to short-term weakness (-12.65% over two weeks), a medium-term rise (33.19% over three months), and a longer-term gain (38.52% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Nanobiotix S.A. (NBTX) stock price?

Nanobiotix S.A. (NASDAQ: NBTX) stock price is $33.05 in the last trading session. During the trading session, NBTX stock reached the peak price of $35.23 while $33.01 was the lowest point it dropped to. The percentage change in NBTX stock occurred in the recent session was -7.89% while the dollar amount for the price change in NBTX stock was - $2.83.

NBTX's industry and sector of operation?

The NASDAQ listed NBTX is part of Biotechnology industry that operates in the broader Healthcare sector. Nanobiotix S.A. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NBTX?

Mr. Earl J. Bergey Ph.d.
Co-Founder
Ms. Kathryn M. McNeil
Senior Vice President of Investor Relations
Prof. Para Prasad Ph.D.
Co-Founder and Member of Scientific Board
Mr. Laurent Levy Ph.D.
Co-Founder, Pres of the Executive Board & Chief Executive Officer
Mr. Bart Van Rhijn
Chief Financial Officer & Member of Executive Board
Mr. Alain Dostie
Chief Operating Officer
Ms. Elsa Borghi
Head of Innovation & Drug Discovery
Ms. Anne-Juliette Hermant M.A.
Chief People Officer & Member of Executive Board
Ms. Sarah Gaubert
Head of Communication & Public Affairs Department
Ms. Margaret Galluzzi
Vice President & Global Head of Clinical Operations
Mr. Patrick Tricoli M.B.A., Pharm.D.
Global Head of Bus. Devel.
Mr. Ventzislav Vassilev M.D.
Vice President & Global Head of Safety Vigilance

How NBTX did perform over past 52-week?

NBTX's closing price is 212.38% higher than its 52-week low of $12.63 where as its distance from 52-week high of $57.14 is -42.16%.

How many employees does NBTX have?

Number of NBTX employees currently stands at 97.

Link for NBTX official website?

Official Website of NBTX is: https://www.nanobiotix.com

How do I contact NBTX?

NBTX could be contacted at phone 331 402 60470 and can also be accessed through its website. NBTX operates from 60 rue de Wattignies, Paris, IF 75012, France.

How many shares of NBTX are traded daily?

NBTX stock volume for the day was 149.34K shares. The average number of NBTX shares traded daily for last 3 months was 139.03K.

What is the market cap of NBTX currently?

The market value of NBTX currently stands at $1.67B with its latest stock price at $33.05 and 50.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	97
Beta	0.57
Sales or Revenue	$30.06M
5Y Sales Change%	3.612%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NBTX Company Profile and Key Details

Nanobiotix SA

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Valuation Metrics

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways